Biotech Values

[DewDiligence]

MYL tells TEVA to shove it:

http://finance.yahoo.com/news/mylan-board-unanimously-rejects-unsolicited-131900773.html

For the sake of your current and future shareholders, employees, patients, customers, communities and other stakeholders, I do hope you find a way to eventually change Teva's culture and establish credibility in your business dealings. However, we do not wish to make Teva's problems Mylan's problems, or to inflict them on Mylan's shareholders and other stakeholders.

…Our Board will certainly not consider engaging in discussions to sell the Company unless the starting point of the discussions is significantly in excess of $100 per share.